Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Alternatively spliced MEFV transcript lacking exon 2 and its protein isoform pyrin-2d implies an epigenetic regulation of the gene in inflammatory cell culture models.

Erdem GC, Erdemir S, Abaci I, Aydin AKK, Everest E, Turanli ET.

Genet Mol Biol. 2017 Jul-Sep;40(3):688-697. doi: 10.1590/1678-4685-GMB-2016-0234. Epub 2017 Aug 31.

2.

Clinicopathological and prognostic characteristics in patients with AFP-secreting gastric carcinoma.

Bozkaya Y, Demirci NS, Kurtipek A, Erdem GU, Ozdemir NY, Zengin N.

Mol Clin Oncol. 2017 Aug;7(2):267-274. doi: 10.3892/mco.2017.1288. Epub 2017 Jun 8.

3.

Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?

Demirci NS, Dogan M, Erdem GU, Kacar S, Turhan T, Kilickap S, Cigirgan LC, Kayacetin E, Bozkaya Y, Zengin N.

Saudi J Gastroenterol. 2017 May-Jun;23(3):183-189. doi: 10.4103/sjg.SJG_483_16.

4.

The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma.

Bozkaya Y, Doğan M, Yazıcı O, Erdem GU, Demirci NS, Zengin N.

Bosn J Basic Med Sci. 2017 May 20;17(2):138-143. doi: 10.17305/bjbms.2017.1684.

5.

Serum IL-17A in Behçet's disease.

Emiroglu N, Cengiz FP, Erdem GB.

Postepy Dermatol Alergol. 2015 Oct;32(5):358-61. doi: 10.5114/pdia.2015.54745. Epub 2015 Oct 29.

6.

Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.

Pitcher A, Emberson J, Lacro RV, Sleeper LA, Stylianou M, Mahony L, Pearson GD, Groenink M, Mulder BJ, Zwinderman AH, De Backer J, De Paepe AM, Arbustini E, Erdem G, Jin XY, Flather MD, Mullen MJ, Child AH, Forteza A, Evangelista A, Chiu HH, Wu MH, Sandor G, Bhatt AB, Creager MA, Devereux RB, Loeys B, Forfar JC, Neubauer S, Watkins H, Boileau C, Jondeau G, Dietz HC, Baigent C.

Am Heart J. 2015 May;169(5):605-12. doi: 10.1016/j.ahj.2015.01.011. Epub 2015 Feb 12.

7.

Metabolic and Histopathological Effects of Fructose Intake During Pregestation, Gestation and Lactation in Rats and their Offspring.

Sarı E, Yeşilkaya E, Bolat A, Topal T, Altan B, Fidancı K, Saldır M, Erdem G, Gülgün M, Kurt YG, Güven A.

J Clin Res Pediatr Endocrinol. 2015 Mar;7(1):19-26. doi: 10.4274/jcrpe.1776.

8.

Anomalous origin and interarterial course of right coronary artery associated with angina and proven ischemia.

Izgi C, Feray H, Erdem G, Kaya Z.

Int J Angiol. 2014 Dec;23(4):271-4. doi: 10.1055/s-0033-1349165.

9.
10.

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Goker H, Baslar Z, Ferhanoglu B.

Ann Hematol. 2015 Mar;94(3):415-20. doi: 10.1007/s00277-014-2215-9. Epub 2014 Sep 18.

11.

Unusual drainage of the main kidney on accessory kidney.

Erdem G, Uğraş M, Demiröz S.

Turk J Urol. 2014 Jun;40(2):120-3. doi: 10.5152/tud.2014.60487.

12.

A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.

Mullen MJ, Flather MD, Jin XY, Newman WG, Erdem G, Gaze D, Valencia O, Banya W, Foley CE, Child A.

Trials. 2013 Dec 1;14:408. doi: 10.1186/1745-6215-14-408.

13.

A rare presentation of follicular lymphoma: cerebellar involvement, successfully treated with a combination of radiotherapy and chemotherapy.

Karadurmus N, Ataergin S, Erdem G, Cakar M, Emer O, Ozaydin S, Ozturk M, Safali M, Arpaci F.

Cancer Res Treat. 2013 Sep;45(3):234-8. doi: 10.4143/crt.2013.45.3.234. Epub 2013 Sep 30.

14.

Intervention with substance-abusing runaway adolescents and their families: results of a randomized clinical trial.

Slesnick N, Erdem G, Bartle-Haring S, Brigham GS.

J Consult Clin Psychol. 2013 Aug;81(4):600-14. doi: 10.1037/a0033463.

15.

Efficacy of ecologically-based treatment with substance-abusing homeless mothers: substance use and housing outcomes.

Slesnick N, Erdem G.

J Subst Abuse Treat. 2013 Nov-Dec;45(5):416-25. doi: 10.1016/j.jsat.2013.05.008. Epub 2013 Jul 25.

16.

Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design.

Kotecha D, Manzano L, Altman DG, Krum H, Erdem G, Williams N, Flather MD; Beta-Blockers in Heart Failure Collaborative Group.

Syst Rev. 2013 Jan 18;2:7. doi: 10.1186/2046-4053-2-7.

17.
18.

Intervention for homeless, substance abusing mothers: findings from a non-randomized pilot.

Slesnick N, Erdem G.

Behav Med. 2012;38(2):36-48. doi: 10.1080/08964289.2012.657724.

19.

Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease.

Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, Tamamoto A, Erdem G, Dodd D, Burns JC.

J Pediatr. 2012 Sep;161(3):506-512.e1. doi: 10.1016/j.jpeds.2012.02.048. Epub 2012 Apr 6.

20.

Emergence of erythromycin- and clindamycin-resistant Streptococcus pyogenes emm 90 strains in Hawaii.

Chen I, Kaufisi P, Erdem G.

J Clin Microbiol. 2011 Jan;49(1):439-41. doi: 10.1128/JCM.02208-10. Epub 2010 Nov 10.

Supplemental Content

Loading ...
Support Center